Arbekacin Activity against Contemporary Clinical Bacteria Isolated from Patients Hospitalized with Pneumonia.
Antimicrob Agents Chemother. 2015 Mar 23;
Authors: Sader HS, Rhomberg PR, Farrell DJ, Jones RN
Abstract
Arbekacin is a broad-spectrum aminoglycoside licensed for systemic use in Japan and under clinical development as an inhalation solution in the United States (USA). We evaluated the occurrence of organisms isolated from pneumonias in USA hospitalized patients (PHP), including ventilator-associated pneumonia (VAP), and the in vitro activity of arbekacin. Organism frequency was evaluated from a collection of 2,203 bacterial isolates (339 from VAP) consecutively collected from 25 medical centers in 2012 through the SENTRY Antimicrobial Surveillance Program. Arbekacin activity was tested against 904 isolates from PHP collected in 2012 from 62 USA medical centers and 303 multidrug-resistant (MDR) organisms collected worldwide in 2009 and 2010 from various infection types. Susceptibility to arbekacin and comparator agents was evaluated by the reference broth microdilution method. The four most common organisms from PHP were Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella spp. and Enterobacter spp. The highest arbekacin MIC value among S. aureus from PHP (43% MRSA) was 4 μg/ml. Against P. aeruginosa from PHP, only one strain had an arbekacin MIC of >16 μg/ml (MIC50/90, 1/4 μg/ml), and susceptibility rates for gentamicin, tobramycin and amikacin were 88.0, 90.0 and 98.0%, respectively. Arbekacin (MIC50, 2 μg/ml) and tobramycin (MIC50, 4 μg/ml) were the most potent aminoglycosides tested against Acinetobacter baumannii. Against Enterobacteriaceae from PHP, arbekacin and gentamicin (MIC50/90, 0.25-1/1-8 μg/ml for both compounds) were generally more potent than tobramycin (MIC50/90, 0.25-2/1-32 μg/ml) and amikacin (MIC50/90, 1-2/2-32 μg/ml). Arbekacin also demonstrated potent in vitro activity against a worldwide collection of well characterized MDR Gram-negative and MRSA strains.
PMID: 25801559 [PubMed - as supplied by publisher]